Application of berberine derivative NBD-125 in preparation of photosensitive antitumor drugs
By improving the structure of berberine derivative NBD-125, the problem of insufficient solubility and selectivity of existing photosensitizers is solved, stronger phototoxicity and anti-cancer activity are achieved, and the effect of photodynamic therapy is significantly improved. Maintained biosafety.
Patent Information
- Application Number
- CN202411252370.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-09
- Publication Date
- 2024-11-12
AI Technical Summary
Existing photosensitizers have poor solubility in solution, easy to quench fluorescence, high toxicity, poor tumor selectivity and targeting, making it difficult to effectively treat tumors.
The berberine derivative NBD-125 was developed, which improved its solubility, bioavailability and photosensitive by improving its structure. As a new photosensitive anti-tumor drug, combined with photodynamic therapy, it showed stronger performance on a variety of cancer cells. Phototoxicity and anti-cancer activity.
NBD-125 significantly improves the killing and tumor suppressive effects on a variety of cancer cells in photodynamic therapy, while maintaining low toxic side effects, showing good biosafety and photostability.
Smart Images

Figure CN118924897A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of photosensitivity anti-tumor, and specifically relates to the application of berberine derivative NBD-125 in the preparation of photosensitivity anti-tumor drugs. Background Art
[0002] Photodynamic therapy (PDT) is a treatment method based on photosensitizers, oxygen and excitation light, in which photosensitizers are the key to PDT treatment. At present, most photosensitizers have the disadvantages of poor solubility, easy fluorescence quenching after aggregation in solution, high toxicity, poor tumor selectivity and targeting. Plants are natural sources of medicinal compounds, and many potential new compounds with photosensitizing properties have been found in plants. Compared with single therapy regimens, the combined use of PDT and phytochemicals can effectively enhance PDT and overcome drug resistance. Berberine (also known as berberine, English name Berberine, abbreviated as BBR) is an alkaloid extracted from medicinal plants such as Coptis chinensis and Phellodendron chinense. It is a natural photosensitizer, but it still has the problems of weak photosensitivity, poor solubility and bioavailability. Berberine derivative NBD-125 (berberine derivative NBD-125, abbreviated as B-125, B125) is a derivative of berberine, and its solubility and bioavailability are significantly improved, but whether it has photosensitizing anti-tumor effects has not been disclosed. Summary of the invention
[0003] The purpose of the present invention is to provide the use of berberine derivative NBD-125 in the preparation of photosensitizing anti-tumor drugs. The present invention finds that berberine derivative NBD-125 can be used as photosensitizing anti-tumor drugs.
[0004] The present invention provides application of berberine derivative NBD-125 in preparing photosensitizing anti-tumor drugs.
[0005] The present invention also provides the use of the berberine derivative NBD-125 in the preparation of photosensitizing anti-colorectal cancer drugs.
[0006] The present invention also provides the use of the berberine derivative NBD-125 in the preparation of photosensitizing anti-melanoma drugs.
[0007] The present invention also provides the use of the berberine derivative NBD-125 in the preparation of photosensitizing anti-breast cancer drugs.
[0008] Preferably, the structure of the berberine derivative NBD-125 is as shown in Formula I:
[0009]
[0010] The present invention provides the use of a berberine derivative NBD-125 in the preparation of a photosensitizing anti-tumor drug. The berberine derivative NBD-125 has a photosensitizing anti-tumor effect, and has better photosensitizing anti-tumor activity, better solubility and bioavailability than berberine, and retains the high tumor selectivity and low toxic side effects of berberine. The results of spectral experiments showed that B125 absorbed light more strongly than BBR and produced a higher fluorescence intensity. B125 had better anti-fluorescence quenching properties, higher quantum yield, longer fluorescence lifetime and better photostability than CE6 (dihydrochlorin e6). The results of cell experiments showed that the phototoxicity of B125 to cancer cells increased with the increase of B125 concentration and the increase of light intensity. The uptake of B125 by cancer cells RKO and HCT116 was much higher than that of normal cells HIEC-6, which was beneficial to the safety of B125. The comparison of the phototoxicity of B125 and BBR to various cancer cells (colorectal cancer cells RKO, colorectal cancer cells HCT116, melanoma cells B16 and human breast cancer cells MDA-MB-231) showed that B125 showed stronger phototoxicity to various cancer cells than BBR, and its anticancer activity was greatly improved. The results of in vivo anti-tumor test of B125 photodynamic therapy showed that B125 photodynamic therapy showed good tumor inhibition effect. B125 has good biological safety of photodynamic therapy. BRIEF DESCRIPTION OF THE DRAWINGS
[0011] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0012] Figure 1 The absorption spectra and fluorescence emission spectra of B125 and BBR provided by the present invention; wherein, (A) UV-visible absorption spectra of B125 and BBR; (B) fluorescence emission spectra of B125 and BBR;
[0013] Figure 2 A comparison result diagram of the optical properties of B125 and CE6 provided by the present invention; wherein, (A) a comparison result diagram of the fluorescence quenching properties of B125 and CE6; (B) a comparison result diagram of the quantum yield of B125 and CE6; (C) a comparison result diagram of the fluorescence lifetime of B125 and CE6; (D) a comparison result diagram of the fluorescence stability of B125 and CE6;
[0014] Figure 3The cytotoxicity and tumor cell selectivity results of B125 provided by the present invention are shown in Figure 1; (A) the toxicity comparison result of B125 on RKO, HCT116 and HIEC-6 cells under dark conditions; (B) the uptake of B125 by RKO, HCT116 and HIEC-6 cells detected by flow cytometry, which is a statistical graph of the ratio of the autofluorescence intensity of B125; (C) 2.5 mW / cm 2 Comparison of the toxicity of B125 to RKO, HCT116 and HIEC-6 cells under light illumination; (D) 5mW / cm 2 Comparison of the toxicity of B125 on RKO, HCT116 and HIEC-6 cells under light; t-test: ns indicates no statistical difference, *p<0.05, **p<0.01, ***p<0.001;
[0015] Figure 4 A comparison of the phototoxicity of B125 and BBR provided by the present invention on various cancer cells;
[0016] Figure 5 The in vivo anti-tumor effect diagram of B125 photodynamic therapy provided by the present invention; wherein, (A) nude mouse tumor volume growth curve diagram of different treatment groups; (B) nude mouse tumor weight statistics diagram of different treatment groups; (C) nude mouse body weight curve diagram of different treatment groups; (D) nude mouse melanoma tumor size pictures of different treatment groups; data: mean ± SD, n = 5; ***P < 0.001;
[0017] Figure 6 This is a graph showing the biosafety results of the B125 photodynamic therapy provided by the present invention. DETAILED DESCRIPTION
[0018] The present invention provides the use of a berberine derivative NBD-125 (also known as a berberine derivative NBD-125, abbreviated as B-125, B125, with a molecular weight of 326.09) in the preparation of photosensitizing anti-tumor drugs. The present invention does not specifically limit the source of the berberine derivative NBD-125, and it can be prepared by conventional methods, such as the patent with application number "201910484491.4" and invention name "A berberine derivative NBD-125 and its application". In the present invention, the structure of the berberine derivative NBD-125 is shown in Formula I:
[0019]
[0020] The berberine derivative NBD-125 of the present invention has better solubility, higher anticancer activity, better bioavailability, high tumor selectivity and low toxic side effects. The present invention found that B125 has strong fluorescence, strong photostability, long fluorescence lifetime and high quantum yield, and for the first time discovered the use of B125 as an anti-tumor photosensitizer. While retaining the excellent tumor cell selectivity of BBR, B125 exhibits stronger phototoxicity than BBR to a variety of cancer cells, and its anticancer activity is greatly improved. In animal experiments, B125 photodynamic therapy also showed good tumor inhibition effect and biosafety. Therefore, B125 is a new photosensitizer that can be used for photodynamic therapy of tumors. In the present invention, when the photosensitive anti-tumor drug is used, the light source condition is preferably a 400-410nm spotlight LED lamp; the use power is preferably 2.5-5mW / cm 2 , more preferably 2.5 mW / cm 2 or 5mW / cm 2 .
[0021] The present invention also provides the use of berberine derivative NBD-125 in the preparation of photosensitizing anti-colorectal cancer drugs. The present invention also provides the use of berberine derivative NBD-125 in the preparation of photosensitizing anti-melanoma drugs. The present invention also provides the use of berberine derivative NBD-125 in the preparation of photosensitizing anti-breast cancer drugs. The test results show that B125 exhibits stronger phototoxicity than BBR to various cancer cells, and the anticancer activity is greatly improved.
[0022] To further illustrate the present invention, the application of the berberine derivative NBD-125 provided by the present invention in the preparation of photosensitizing anti-tumor drugs is described in detail below in conjunction with the accompanying drawings and examples, but they should not be construed as limiting the scope of protection of the present invention.
[0023] Example 1
[0024] Absorption and fluorescence spectroscopy
[0025] The UV-visible absorption spectrum was detected by a UV-visible spectrophotometer, and the fluorescence spectrum was measured by a fluorescence spectrophotometer. First, 1×PBS buffer solution with a pH of 7.4 and a drug storage solution were prepared, and a suitable concentration gradient was set. The storage solution was diluted in a PBS solution, 3 mL of the working solution was placed in a standard quartz cuvette, and the UV-visible absorption spectrum of the substance was obtained by scanning with a UV spectrophotometer; 3 mL of the working solution was placed in a standard quartz cuvette (four-way), and the fluorescence spectrum of the substance was measured using a fluorescence spectrophotometer, with the excitation and emission slits being 5 nm.
[0026] B125 and BBR powders were dissolved in PBS solution to prepare 20mM storage solutions respectively. 60μL of the storage solution was diluted to 3mL with PBS to obtain 40μM B125 and BBR solutions. The absorption spectra of B125 and BBR were detected by UV-Vis spectrophotometer. The results showed that the absorption light bands of B125 and BBR were both in the blue-violet light region. In PBS solution, the UV-Vis absorption spectrum of BBR reached a peak at 425nm, while that of B125 reached a peak at 405nm.
[0027] The same conversion method was used to dilute the storage solution to make the concentration of B125 2μM and the concentration of BBR 2mM. The fluorescence intensity of BBR and B125 under their respective excitation light was detected using a fluorescence spectrophotometer. The fluorescence intensity of B125 was much higher than that of BBR.
[0028] Results Figure 1 , Figure 1 The absorption spectra and fluorescence emission spectra of B125 and BBR are shown in Figure 1. (A) UV-visible absorption spectra of B125 and BBR; (B) fluorescence emission spectra of B125 and BBR. The results show that B125 absorbs light more strongly than BBR and produces higher fluorescence intensity.
[0029] Example 2
[0030] Comparison of optical properties
[0031] Fluorescence quenching properties: The stock solutions of B125 and CE6 (purchased from Shanghai MacLean Biochemical Technology Co., Ltd.) were diluted with PBS to four concentration gradients: 2 μM, 4 μM, 20 μM, and 50 μM. Under the same conditions, the intensity of the emission spectra of B125 and CE6 changed with concentration using a fluorescence spectrophotometer.
[0032] Quantum yield and fluorescence lifetime: Prepare 3 mL of 2 μM B125 and CE6 solution and directly detect using a steady-state transient fluorescence spectrometer with appropriate modules.
[0033] Photostability: Under the irradiation of 400-410nm LED light, B125 and CE6 solutions emitted green fluorescence and red fluorescence, respectively. The final concentrations of B125 and CE6 were 2μM and 4μM, respectively. PBS was the non-luminescent control group. 3mL of solution was placed in four-way quartz cuvettes. The light was continuously irradiated for 2min and 8min, and the fluorescence changes of B125 and CE6 were observed and recorded by taking pictures.
[0034] Results Figure 2 , Figure 2The figure shows the comparison of the optical properties of B125 and CE6; (A) the comparison of the fluorescence quenching properties of B125 and CE6; (B) the comparison of the quantum yield of B125 and CE6; (C) the comparison of the fluorescence lifetime of B125 and CE6; (D) the comparison of the fluorescence stability of B125 and CE6. The results show that B125 has better anti-fluorescence quenching properties, higher quantum yield, longer fluorescence lifetime and better photostability than CE6.
[0035] Example 3
[0036] Cell experiments
[0037] The MTT assay was used to detect the phototoxicity and dark toxicity of B125 on human colorectal cancer cells RKO (purchased from the cell bank of Shanghai Institute of Cell Biology, Chinese Academy of Sciences), human colorectal cancer cell line HCT116 (purchased from the cell bank of Shanghai Institute of Cell Biology, Chinese Academy of Sciences), and normal intestinal epithelial cells HIEC-6 (purchased from American Type Culture Collection). 4 Cells were inoculated into 96-well plates. After 24 hours of inoculation, medium containing different concentrations of B125 was added for incubation. Dark conditions were as follows: B125 concentration gradient was 0μM, 12.5μM, 25μM, 50μM, 100μM, and incubated for 24 hours. Light conditions were as follows: B125 concentration gradient was 0μM, 1.25μM, 2.5μM, 5μM, 10μM. After B125 was added to the cells for 4 hours, 2.5mW / cm 2 or 5mW / cm 2 Illuminate with a 400-410nm LED light for 5 minutes and continue incubation for 20 hours. Add 20μL of 5mg / mL MTT (protected from light) to each well, react in a cell culture incubator for 4 hours, and then remove the culture medium. Add 150μL DMSO to each well and shake on a shaker for 15 minutes in the dark. Use an enzyme marker to measure the light absorption value (OD value) at 492nm, which can represent the cell survival rate.
[0038] The autofluorescence of B125 was used to detect the uptake of B125 by RKO, HCT116 and HIEC-6. The cells were inoculated in a 12-well plate. The cell density after attachment was 70% to 80%. The concentration of B125 was set to 0μM, 12.5μM, 25μM, and 50μM, with three replicates in each group. After B125 treatment for 4 hours, the cells were carefully washed with PBS to remove the residual B125 in the culture medium, digested and collected, and then washed once with PBS, centrifuged, and resuspended with an appropriate volume of PBS according to the cell volume. The cells were filtered through a 300-mesh filter and then tested on the machine. A 375nm laser was used, and the emission light detection channel was FL9-450 / 45. The data were analyzed using FlowJo software, and the average fluorescence intensity of each cell was calculated and compared with the control group, representing the uptake of B125 by RKO, HCT116 and HIEC-6.
[0039] Results Figure 3 , Figure 3 Figures 2 and 3 show the cytotoxicity and tumor cell selectivity of B125. (A) Comparison of the toxicity of B125 to RKO, HCT116 and HIEC-6 cells under dark conditions. (B) Flow cytometry analysis of the uptake of B125 by RKO, HCT116 and HIEC-6 cells, showing the ratio of the autofluorescence intensity of B125. (C) 2.5 mW / cm 2 Comparison of the toxicity of B125 to RKO, HCT116 and HIEC-6 cells under light illumination; (D) 5mW / cm 2 Comparison of the toxicity of B125 on RKO, HCT116 and HIEC-6 cells under light; t-test: ns indicates no statistical difference, *p<0.05, **p<0.01, ***p<0.001. The results show that the phototoxicity of B125 on cancer cells increases with the increase of B125 concentration and the increase of light intensity; the uptake of B125 by cancer cells RKO and HCT116 is much higher than that of normal cells HIEC-6, which is beneficial to the safety of B125.
[0040] Example 4
[0041] Comparison of phototoxicity of B125 and BBR on various cancer cells
[0042] The phototoxicity of B125 and BBR to colorectal cancer cells RKO, colorectal cancer cells HCT116, melanoma cells B16 and human breast cancer cells MDA-MB-231 was also detected by MTT assay. 4Cells were inoculated into 96-well plates. After 24 hours of inoculation, medium containing different concentrations of B125 or BBR was added for incubation. The concentration gradient of B125 and BBR was set to 0μM, 0.05μM, 0.1μM, 0.2μM, 0.4μM, 0.8μM, 1.6μM, 3.125μM, 6.25μM, 12.5μM, 25μM, and 50μM. After incubation for 4 hours, 5mW / cm 2 , 400-410nm LED light was irradiated for 5 minutes, and the cells were incubated for 20 hours. 20μL of 5mg / mL MTT (added in dark) was added to each well, and the culture medium was removed after 4 hours of reaction in the cell culture incubator. 150μL of DMSO was added to each well, and the cells were shaken in a light-proof shaker for 15 minutes. The light absorption value (OD value) at 492nm was measured using an ELISA reader. The inhibition rate of the drug on cell proliferation was calculated based on the OD values detected at different concentrations and the standard curve. The half inhibition concentration, i.e., IC, was obtained by software fitting. 50 value.
[0043] Results Figure 4 , Figure 4 The comparison results of the phototoxicity of B125 and BBR provided by the present invention on various cancer cells; colorectal cancer cells RKO, colorectal cancer cells HCT116, melanoma cells B16 and human breast cancer cells MDA-MB-231, IC 50 The smaller the value, the stronger the killing effect on cancer cells, ***P<0.001. The results showed that B125 showed stronger phototoxicity than BBR to various cancer cells, and its anticancer activity was greatly improved.
[0044] Example 5
[0045] In vivo antitumor effect of B125 photodynamic therapy
[0046] Animal experiment: SPF BALB / c nude mice aged 5 to 6 weeks and weighing between 22 and 23 g were used for the experiment. Melanoma B16-OVA cells were kept in logarithmic growth phase and the density was maintained at 80%. The corresponding cells were prepared according to the number of mice. After digestion, the cells were resuspended in serum-free medium, counted and diluted to 4×10 cells per 100 μL serum-free medium. 5 The cells were placed on a 4°C ice box and transported to the animal center for a mouse subcutaneous tumor formation experiment. The mice were observed every day, and the volume of the mouse tumor (V = 1 / 2 long diameter × short diameter × short diameter) was measured and recorded with a vernier caliper when the tumor of the mouse required for the experiment grew to an appropriate volume. The tumor size was 50-200 mm. 3Mice were randomly divided into four groups. Tumor-bearing female mice were randomly divided into four groups (n=5): (1) PBS group, (2) PBS+Light group, (3) B125 group, and (4) B125+Light group. Mice in different groups were injected with PBS (100 μL) or B125 (5 mg / kg) by intratumoral injection. After 3 hours of injection, they were irradiated (400-410 nm) for 10 min or not irradiated. The drug was administered once every 2 days for 10 days. During the treatment period, the weight of the mice and the long and short diameters of the tumors were recorded, and the tumor volume was calculated. When the tumor volume of the control group mice reached the ethical critical value, all mice were killed, the transplanted tumors were removed, photographed, and the tumor weight was weighed.
[0047] Results Figure 5 , Figure 5 The in vivo anti-tumor effect of B125 photodynamic therapy is shown in Figure 1. (A) Tumor volume growth curve of nude mice in different treatment groups; (B) Tumor weight statistics of nude mice in different treatment groups; (C) Body weight curve of nude mice in different treatment groups; (D) Pictures of melanoma tumor size of nude mice in different treatment groups; Data: mean ± SD, n = 5; ***P < 0.001. The results show that the B125 + Light group has a significant effect on inhibiting tumor growth in vivo, and B125 photodynamic therapy shows a good tumor inhibition effect.
[0048] Example 6
[0049] B125 Biological safety of photodynamic therapy
[0050] The heart, liver, spleen, lung, kidney and tumor tissues of mice in (1) PBS group, (2) PBS+Light group, (3) B125 group and (4) B125+Light group were cut and fixed in 4% paraformaldehyde solution for HE staining. HE staining experimental steps:
[0051] 1. Fixation: Mouse tissues were fixed in 4% paraformaldehyde in a 4°C refrigerator for 2 days;
[0052] 2. Dehydration: After fixation, put the tissue into the embedding box, mark it with a pencil, and dehydrate it with an automatic dehydrator;
[0053] 3. Embedding: Select the plane with the largest cross-sectional area for embedding;
[0054] 4. Sectioning: Section thickness: 4 μm; mark the adhesive slide with a pencil, carefully pick up the slide, and dry it in a dryer. After baking the slide overnight, use an automatic HE staining machine for HE staining.
[0055] Results Figure 6 , Figure 6The results of the biosafety of B125 photodynamic therapy are shown in Figure 1. Specifically, the representative images of HE staining results of the heart, liver, spleen, lung, kidney and tumor sites of mice in different treatment groups, scale: 50μm. The results showed that there were large areas of apoptosis in the tumor tissue of mice in the B125+Light group, and no substantial damage was found in the staining results of the heart, liver, spleen, lung and kidney of the mice. B125 photodynamic therapy for tumors also showed good biosafety.
[0056] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creative work, and these embodiments all fall within the scope of protection of the present invention.
Claims
1. Application of berberine derivative NBD-125 in the preparation of photosensitizing anti-tumor drugs.
2. Application of berberine derivative NBD-125 in the preparation of photosensitizing anti-colorectal cancer drugs.
3. Application of berberine derivative NBD-125 in the preparation of photosensitizing anti-melanoma drugs.
4. Application of berberine derivative NBD-125 in the preparation of photosensitizing anti-breast cancer drugs.
5. The use according to any one of claims 1 to 4, characterized in that: The structure of the berberine derivative NBD-125 is shown in Formula I:
